We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lockheed Martin Wins Navy Deal to Support CH-53K Aircraft
Read MoreHide Full Article
Lockheed Martin Corp.’s (LMT - Free Report) business unit, Sikorsky, recently secured a contract for procuring CH-53K Data Transfer Unit and Defensive Electronic Countermeasure System Replacement program. The deal was awarded by the Naval Air Systems Command, Patuxent River, Maryland.
Valued at $21.7 million, the contract is expected to be completed in January 2021. The agreement also includes necessary Non-Recurring Engineering (NRE) to replace existing subsystems within the CH-53K production aircraft.
Majority of the work related to the deal will be executed in Stratford, CT, and Cedar Rapids, IA.
A Brief Note on the CH-53K Program
The CH-53K helicopter advances Sikorsky’s 50 years of manufacturing and operational success with its CH-53A, CH-53D/G and CH-53E predecessors. The new heavy lifter allows the U.S. Marine Corps and international militaries to move troops and equipment from ship to shore and higher altitude terrains more quickly and effectively. It is also effective for handling missions like humanitarian aid, troop transport, casualty evacuation, support of special operations forces, and combat search and rescue (CSAR).
What Favors Lockheed Martin?
In recent times, military helicopters in the U.S. aerospace-defense market have gained prominence and significant traction due to advancements and integration of new tactical, logistical and other important features. Some of these developments have also been made by Lockheed Martin, paving the way toward securing valuable helicopter-related contracts in recent times. Such contract wins are indicative of solid revenue growth at the company’s Rotary and Mission Systems (RMS) business segment, which comprises the Sikorsky helicopters. Evidently, during first-quarter 2019, revenues at Lockheed Martin’s RMS unit increased 17% year over year, with its Sikorsky helicopter programs being one of the primary growth contributors.
Furthermore, the latest defense budget proposal for fiscal 2020 offers investment potential worth $57.7 billion in Aircraft, including $0.8 billion for Sikorsky VH-92. Backed by this financial plan, we may expect Lockheed Martin’s RMS unit to obtain consistent order flows from the Pentagon like the latest one. This, in turn, might lead to similar top-line growth for the unit in the coming days.
Price Movement
In a year’s time, shares of Lockheed Martin have gained 23.8% compared with the industry’s 8.1% rise.
Textron delivered average positive earnings surprise of 7.62% in the last four quarters. The Zacks Consensus Estimate for 2019 earnings has moved 0.8% up to $3.70 over the past 90 days.
Northrop delivered average positive earnings surprise of 18.50% in the trailing four quarters. The Zacks Consensus Estimate for 2019 earnings has climbed 1.8% to $19.29 over the past 90 days.
Wesco Aircraft’s long-term growth estimate currently stands at 12%. The Zacks Consensus Estimate for 2019 earnings has moved 3.7% north to 84 cents over the past 90 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Lockheed Martin Wins Navy Deal to Support CH-53K Aircraft
Lockheed Martin Corp.’s (LMT - Free Report) business unit, Sikorsky, recently secured a contract for procuring CH-53K Data Transfer Unit and Defensive Electronic Countermeasure System Replacement program. The deal was awarded by the Naval Air Systems Command, Patuxent River, Maryland.
Valued at $21.7 million, the contract is expected to be completed in January 2021. The agreement also includes necessary Non-Recurring Engineering (NRE) to replace existing subsystems within the CH-53K production aircraft.
Majority of the work related to the deal will be executed in Stratford, CT, and Cedar Rapids, IA.
A Brief Note on the CH-53K Program
The CH-53K helicopter advances Sikorsky’s 50 years of manufacturing and operational success with its CH-53A, CH-53D/G and CH-53E predecessors. The new heavy lifter allows the U.S. Marine Corps and international militaries to move troops and equipment from ship to shore and higher altitude terrains more quickly and effectively. It is also effective for handling missions like humanitarian aid, troop transport, casualty evacuation, support of special operations forces, and combat search and rescue (CSAR).
What Favors Lockheed Martin?
In recent times, military helicopters in the U.S. aerospace-defense market have gained prominence and significant traction due to advancements and integration of new tactical, logistical and other important features. Some of these developments have also been made by Lockheed Martin, paving the way toward securing valuable helicopter-related contracts in recent times.
Such contract wins are indicative of solid revenue growth at the company’s Rotary and Mission Systems (RMS) business segment, which comprises the Sikorsky helicopters. Evidently, during first-quarter 2019, revenues at Lockheed Martin’s RMS unit increased 17% year over year, with its Sikorsky helicopter programs being one of the primary growth contributors.
Furthermore, the latest defense budget proposal for fiscal 2020 offers investment potential worth $57.7 billion in Aircraft, including $0.8 billion for Sikorsky VH-92. Backed by this financial plan, we may expect Lockheed Martin’s RMS unit to obtain consistent order flows from the Pentagon like the latest one. This, in turn, might lead to similar top-line growth for the unit in the coming days.
Price Movement
In a year’s time, shares of Lockheed Martin have gained 23.8% compared with the industry’s 8.1% rise.
Zacks Rank & Key Picks
Lockheed Martin currently carries a Zacks Rank #3 (Hold). A few better-ranked companies in the same space are Textron Inc. (TXT - Free Report) , Northrop Grumman Corp. (NOC - Free Report) and Wesco Aircraft Holdings, Inc. , each carrying a rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Textron delivered average positive earnings surprise of 7.62% in the last four quarters. The Zacks Consensus Estimate for 2019 earnings has moved 0.8% up to $3.70 over the past 90 days.
Northrop delivered average positive earnings surprise of 18.50% in the trailing four quarters. The Zacks Consensus Estimate for 2019 earnings has climbed 1.8% to $19.29 over the past 90 days.
Wesco Aircraft’s long-term growth estimate currently stands at 12%. The Zacks Consensus Estimate for 2019 earnings has moved 3.7% north to 84 cents over the past 90 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>